Bacterial vaginosis treatment
In recent years there has been a rise in vaginal infections falling within the category of obstetric-gynecological disorders and diseases. According to various reports, vaginal infections account for 30-60%, or even up to 80%, of all inflammatory diseases affecting genital organs. Bacterial vaginosis is a risk factor that can cause severe pathology of female genital organs leading to pregnancy and childbirth complications.
Several reports demonstrated there may be a link between bacterial vaginosis and chorioamnionitis, postpartum endometritis, premature birth, low birth-weight babies, inflammatory processes of the genital organs, purulent septic complications affecting the mother and child in the postpartum period, and/or other obstetric and neonatal pathology. Nevertheless, early diagnosis and timely etiotropic therapy can help prevent development of complications and improve the effectiveness of treatment.
Bacterial vaginosis disrupts vaginal microbiocenosis and promotes growth of harmful endogenous microflora. In such cases, proper microflora of the vagina is replaced by other microorganisms including Bacteroides, Fusobacterium, Peptostreptococcus, Veillonellas, Gardnerella, and/or Mycoplasma.
Patients with bacterial vaginosis commonly complain of unusual smelly white or grey discharge from the genital tract, particularly following intercourse or during menstruation. When left untreated unconformable symptoms can last for years. Over time, discharge caused by bacterial vaginosis turns yellow-green, thickens, has an unpleasant smell, and in some instances appear as sticky foam.
For most patients (63.9%) who complain of bacterial vaginosis, this condition developed as a consequence of cervical ectopia, leukoplakia, endocervicitis, and/or endometriosis. Bacterial vaginosis commonly coincides with menstrual cycle disorders in women who have been using the intrauterine contraceptive device or coil longer than five years.
There are many ways to treat bacterial vaginosis. Doctors often prescribe Flagyl (Metronidazole) as a drug of choice for etiotropic therapy of vaginosis. They prefer Flagyl because it demonstrates a broad spectrum of anti-anaerobic action. When attacking a microbial cell, Metronidazole is activated and binds DNA while blocking nucleic acid synthesis. If bacterial vaginosis is diagnosed for the first time, it is recommended that patients take one 500 mg Flagyl tablet twice a day for one week.
The half-life of Flagyl is 8-10 hours and is entirely removed from the body 1-2 days after administration. Flagyl is removed via urine as a metabolite. Flagyl can cause a loss of appetite, dryness and unpleasant taste in the mouth, nausea, vomiting, diarrhea, headache, rashes, and/or itching. These side effects could be expected to go away after Flagyl treatment is stopped.